Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820190 | 0.84 | GABRA1 (0.38) | CYP2A6PDE3BPDE3A | |
| SCHEMBL7471392 | 0.81 | CYP2A6 (0.31) | CYP2A6 | |
| SCHEMBL156074 | 0.75 | CYP2A6 (0.34) | CYP2A6PDE3BPDE3A | |
| SCHEMBL3801869 | 0.73 | NOS2 (0.38) | CYP2A6PDE3BPDE3A | |
| SCHEMBL4795960 | 0.71 | KDM4E (0.41) | CYP2A6 | |
| SCHEMBL7396568 | 0.71 | CYP2A6 (0.34) | CYP2A6 | |
| SCHEMBL1931165 | 0.71 | LOXL2 (0.45) | CYP2A6 | |
| SCHEMBL28201879 | 0.69 | CYP2A6 (0.33) | CYP2A6 | |
| SCHEMBL10647777 | 0.68 | DYRK1A (0.40) | CYP2A6 | |
| SCHEMBL7696876 | 0.67 | CYP2A6 (0.31) | CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | CYP2A6 2951/4885PDE3B 479/4885PDE3A 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.